Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/40409
Title: PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY
Authors: Gragnano, F
Heg, D
Franzone, A
McFadden, EP
Leonardi, S
Piccolo, R
VRANCKX, Pascal 
Branca, M
Serruys, PW
Benit, E
Liebetrau, C
Janssens, L.
Ferrario, M
Zurakowski, A
Diletti, R
Dominici, M
Huber, K
Slagboom, T
Buszman, P
Bolognese, L
Tumscitz, C
Bryniarski, K
Aminian, A
Vrolix, M
Petrov, I
Garg, S
Naber, C
Prokopczuk, J
Hamm, C
Steg, PG
Juni, P
Windecker, S
Valgimigli, M
Issue Date: 2022
Publisher: OXFORD UNIV PRESS
Source: European Heart Journal-Cardiovascular Pharmacotherapy, 8 (1) , p. 28 -38
Abstract: Aims The five-item PRECISE-DAPT, integrating age, haemoglobin, white-blood-cell count, creatinine clearance, and prior bleeding, predicts bleeding risk in patients on dual antiplatelet therapy (DAPT) after stent implantation. We sought to assess whether the bleeding risk prediction offered by the PRECISE-DAPT remains valid among patients receiving ticagrelor monotherapy from 1 month onwards after coronary stenting instead of standard DAPT and having or not having centrally adjudicated bleeding endpoints.Methods and results The PRECISE-DAPT was calculated in 14 928 and 7134 patients from GLOBAL LEADERS and GLASSY trials, respectively. The ability of the score to predict Bleeding Academic Research Consortium 3 or 5 bleeding was assessed and compared among patients on ticagrelor monotherapy (experimental strategy) or standard DAPT (reference strategy) from 1 month after drug-eluting stent implantation. Bleeding endpoints were investigatorreported or centrally adjudicated in GLOBAL LEADERS and GLASSY, respectively. At 2 years, the c-indexes for the score among patients treated with the experimental or reference strategy were 0.67 [95% confidence interval (CI): 0.63-0.71] vs. 0.63 (95% CI: 0.59-0.67) in GLOBAL LEADERS (P = 0.27), and 0.67 (95% CI: 0.61-0.73) vs. 0.66 (95% CI: 0.61-0.72) in GLASSY (P = 0.88). Decision curve analysis showed net benefit using the PRECISEDAPT to guide bleeding risk assessment under both treatment strategies. Results were consistent between investigator-reported and adjudicated endpoints and using the simplified four-item PRECISE-DAPT.Conclusion The PRECISE-DAPT offers a prediction model that proved similarly effective to predict clinically relevant bleeding among patients on ticagrelor monotherapy from 1 month after coronary stenting compared with standard DAPT and appears to be unaffected by the presence or absence of adjudicated bleeding endpoints.
Keywords: Dual antiplatelet therapy;Ticagrelor;Aspirin;Bleeding;Percutaneous coronary intervention
Document URI: http://hdl.handle.net/1942/40409
ISSN: 2055-6837
e-ISSN: 2055-6845
DOI: 10.1093/ehjcvp/pvaa106
ISI #: 000743681300007
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
pvaa106.pdfPublished version910.81 kBAdobe PDFView/Open
Show full item record

WEB OF SCIENCETM
Citations

36
checked on May 8, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.